---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-014880"
form_type: "8-K"
ticker: "MNPR"
cik: "0001645469"
company_name: "Monopar Therapeutics"
filed_at: "2025-05-07T23:59:59+00:00"
generated_at: "2026-05-22T08:17:58.857638+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Monopar presents ALXN1840 late-breaker data at EASL showing sustained efficacy and safety over 2.6 years

## Summary
- Pooled analysis from three trials (n=255) shows sustained improvements in UWDRS Part II/III and copper mobilization.
- Fewer than 5% of patients had a drug-related serious adverse event; no renal/urinary SAEs reported.
- ALXN1840 improved CGI-I and New Wilson Index vs. standard of care; patients reported higher convenience.
- Median treatment duration 961 days (efficacy) and 943.5 days (safety) across four trials.

## SEC filing metadata
- accession: 0001437749-25-014880
- form_type: 8-K
- ticker: MNPR
- cik: 0001645469
- company_name: Monopar Therapeutics
- filed_at: 2025-05-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645469/000143774925014880/0001437749-25-014880-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645469/000143774925014880/mnpr20250505_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-014880
- JSON: https://secwatch.observer/filing/0001437749-25-014880.json
- Plain text: https://secwatch.observer/filing/0001437749-25-014880.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.